Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Jan 20;9(1):e85782.
doi: 10.1371/journal.pone.0085782. eCollection 2014.

Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis

Miao He  1 , Wei Wang  1 , Xiulan Zhang  1 , Wenyong Huang  1
Affiliations
Meta-Analysis

Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis

Miao He et al. PLoS One. .

Abstract

Objective: To evaluate the application of the Ologen implant compared to mitomycin C (MMC) on the outcome of trabeculectomy and to examine the balance of risks and benefits.

Methods: A systematic literature search (Pubmed, Embase, the Cochrane Library, and the Chinese Biomedicine Database) was performed. Randomized controlled trials comparing the Ologen implant with MMC in trabeculectomy were selected. The efficacy measures were the weighted mean differences (WMDs) for the intraocular pressure reduction (IOPR), the reduction in glaucoma medications, and the relative risks (RRs) for success rates. The tolerability measures were RRs for adverse events. The pooled effects were calculated using the random-effects model.

Results: Seven randomized controlled trials including 227 eyes were included in this meta-analysis. The WMDs of the IOPR comparing the Ologen group with the MMC group were -2.98 (95% Cl: -5.07 to -0.89) at one month, -1.41 (-3.72 to 0.91) at three months, -1.69 (-3.68 to 0.30) at six months, -1.94 (-3.88 to 0.01) at 12 months, and 0.65 (-2.17 to 0.47) at 24 months. There was no statistically significance except at one and 12 months after surgery. No significant difference in the reduction in glaucoma medications or complete and qualified success rates were found. The rates of adverse events also did not differ significantly between Ologen and MMC.

Conclusions: The Ologen implant is comparable with MMC for trabeculectomy in IOP-lowering efficacy, reduction in the number of glaucoma medications, success rates, and tolerability. However, the results should be interpreted cautiously since relevant evidence is still limited, although it is accumulating. Further large-scale, well-designed randomized controlled trials are urgently needed.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow of randomized controlled trials included in the meta-analysis.
Figure 2
Figure 2. The weighted mean differences of the reduction in intraocular pressure between trabeculectomy with Ologen implant and with intraoperative mitomycin C. WMD indicates weighted mean difference, which were computed by using a random effects model.
See this image and copyright information in PMC

References

    1. Razeghinejad MR, Fudemberg SJ, Spaeth GL (2012) The changing conceptual basis of trabeculectomy: A review of past and current surgical techniques. Survey of Ophthalmology 57: 1–25. - PubMed
    1. Rao K, Ahmed I, Blake DA, Ayyala RS (2009) New devices in glaucoma surgery. Expert Review of Ophthalmology 4: 491–504.
    1. Lockwood A, Brocchini S, Khaw PT (2013) New developments in the pharmacological modulation of wound healing after glaucoma filtration surgery. Curr Opin Pharmacol 13: 65–71. - PubMed
    1. Wang W, Zhou M, Huang W, Zhang X (2013) Ex-PRESS Implantation Versus Trabeculectomy in Uncontrolled Glaucoma: A Meta-Analysis. PLoS One 8: e63591. - PMC - PubMed
    1. Husain R, Clarke JC, Seah SK, Khaw PT (2005) A review of trabeculectomy in East Asian people–the influence of race. Eye (Lond) 19: 243–252. - PubMed